Therapeutic modulation of urinary bladder function: Multiple targets at multiple levels

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 269-287

  Michel, Martin C ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Afferent nerve; Muscarinic receptor antagonist; Urothelium; 1 adrenoceptor antagonist; adrenoceptor agonist

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BOTULINUM TOXIN A; MUSCARINIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; URINARY TRACT AGENT;

BLADDER DISEASE; BLADDER FIBROSIS; BLADDER FUNCTION; BLADDER HYPERTROPHY; DENERVATION; EFFERENT NERVE; FIBROSIS; HUMAN; HYPERTROPHY; MORPHOLOGY; NERVE ENDING; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SENSORY NERVE; SMOOTH MUSCLE FIBER; UROTHELIUM; VASCULARIZATION; ANIMAL; BLADDER; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; INNERVATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SENSORY NERVE CELL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; TREATMENT OUTCOME; URINARY BLADDER DISEASES; URODYNAMICS;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-AGONISTS; ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; MUSCARINIC ANTAGONISTS; MUSCLE, SMOOTH; NEURONS, AFFERENT; NEURONS, EFFERENT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER DISEASES; URODYNAMICS; UROLOGICAL AGENTS; UROTHELIUM;

EID: 84920854486     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124536     Document Type: Review

References (152)

1. Michel MC, Chapple CR. 2009. Basic mechanisms of urgency: basic and clinical evidence. Eur. Urol. 56:298-308
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, et al. 2002. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol. Urodyn. 21:167-78
3. Barendrecht MM, Oelke M, Laguna MP, Michel MC. 2007. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int. 99:749-52
4. Osman NI, Chapple CR, Abrams P, Dmochowski R, Haab F, et al. 2014. Detrusor underactivity and the underactive bladder: A new clinical entity? A review of current terminology, definitions, epidemiology, aetiology and diagnosis. Eur. Urol. 65:389-98
5. Michel MC, De La Rosette JJM CH, Piro M, Goepel M. 2004. Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? J. Urol. 172:601-4
6. Michel MC, Oelke M, Peters SLM. 2005. The neuro-urological connection. Eur. Urol. Suppl. 4:18-28
7. Coyne KS, Zhou Z, Thompson C, Versi E. 2003. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int. 92:731-35
8. Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR. 2012. Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. Eur. Urol. 61:88-95
9. Margareta N, Ann L, Othon L. 2009. The impact of female urinary incontinence and urgency on quality of life and partner relationship. Neurourol. Urodyn. 28:976-81
10. Irwin DE, Milsom I, Kopp Z, Abrams P. 2008. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur. Urol. 53:1029-39
11. Stewart WF, van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, et al. 2003. Prevalence and burden of overactive bladder in the United States. World J. Urol. 20:327-36
12. Milsom I, Abrams P, Cardozo L, Roberts RG, Th uroff JW, Wein AJ. 2001. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87:760-66
13. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, et al. 2006. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 50:1306-15
14. Goepel M, Hoffmann J, Piro M, Rubben H, Michel MC. 2002. Prevalence and physician awareness of symptoms of urinary bladder dysfunction. Eur. Urol. 41:234-39
15. Krege S, Kinzig-Schppers M, S orgel F, Baschek R, Michel MC, Rubben H. 2004. Absorption of intravesically applied drugs: comparison of normal and ileal-augmented rabbit bladder. J. Urol. 172:2045-50
16. Birder LA, de Groat WC. 2007. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat. Clin. Pract. Urol. 4:46-54
17. Andersson K-E, McCloskey KD. 2014. Lamina propria: the functional center of the bladder? Neurourol. Urodyn. 33:9-16
18. Takeda M, Mochizuki T, Yoshiyama M, Nakagomi H, Kobayashi H, et al. 2010. Sensor mechanism and afferent signal transduction of the urinary bladder: special focus on transient receptor potential ion channels. LUTS Lower Urin. Tract Symptoms 2:51-60
19. Ochodnicky P, Humphreys S, Eccles R, Poljakovic M, Wiklund P, Michel MC. 2012. Expression profiling of G-protein-coupled receptors in human urothelium and related cell lines. BJU Int. 110:e293-300
20. Bahadory F, Moore KH, Liu L, Burcher E. 2013. Gene expression of muscarinic, tachykinin, and purinergic receptors in porcine bladder: comparison with cultured cells. Front. Pharmacol. 4:148
21. Tully BT, Li M, Sun Y, Berkowitz J, Chai TC. 2009. Defects in muscarinic receptor cell signaling in bladder urothelial cancer cell lines. Urology 74:467-73
22. Chopra B, Barrick SR, Meyers S, Beckel JM, Zeidel ML, et al. 2005. Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium. J. Physiol. 562:859-71
23. Birder LA, Nealen ML, Kiss S, de Groat WC, Caterina MJ, et al. 2002. β-Adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J. Neurosci. 22:8063-70
24. Harmon EB, Porter JM, Porter JE. 2005. β-adrenergic receptor activation in immortalized human urothelial cells stimulates inflammatory responses by PKD-independent mechanisms. Cell Commun. Signal. 3:10
25. Kumar V, Cross RL, Chess-Williams R, Chapple CR. 2005. Recent advances in basic science for overactive bladder. Curr. Opin. Urol. 15:222-26
26. Lips KS, Wunsch J, Sarghooni S, Bschleipfer T, Schukowski K, et al. 2007. Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. Eur. Urol. 51:1042-53
27. Yoshida M, Masunaga K, Satoji Y, Maeda Y, Nagata T, Inadome A. 2008. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance. J. Pharmacol. Sci. 106:193-98
28. Ochodnicky P, Michel-Reher MB, Butter JJ, Seth J, Panicker JN, Michel MC. 2013. Bradykinin modulates spontaneous nerve growth factor production and stretch-inducedATPrelease in human urothelium. Pharmacol. Res. 70:147-54
29. Yokoyama O, Tanaka I, Kusukawa N, Yamauchi H, Ito H, et al. 2011. Antimuscarinics suppress adenosine triphosphate and prostaglandin E2 release from urothelium with potential improvement in detrusor overactivity in rats with cerebral infarction. J. Urol. 185:2392-97
30. Ochodnicky P, Cruz CD, Yoshimura N, Michel MC. 2011. Nerve growth factor in bladder dysfunction: contributing factor, biomarker and therapeutic target. Neurourol. Urodyn. 30:1227-41
31. Andersson MC, Tobin G, Giglio D. 2008. Cholinergic nitric oxide release from the urinary bladder mucosa in cyclophosphamide-induced cystitis of the anaesthetized rat. Br. J. Pharmacol. 153:1438-44
32. Bschleipfer T, Weidner W, Kummer W, Lips KS. 2012. Does bladder outlet obstruction alter the non-neuronal cholinergic system of the human urothelium? Life Sci. 91:1082-86
33. Anisuzzaman AS, Morishima S, Suzuki F, Tanaka T, Yoshiki H, et al. 2008. Assessment of muscarinic receptor subtypes in human and rat lower urinary tract by tissue segment binding assay. J. Pharmacol. Sci. 106:271-79
34. Zarghooni S, Wunsch J, Bodenbenner M, Br uggmann D, Grando SA, et al. 2007. Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. Life Sci. 80:2308-13
35. Grol S, Essers PBM, van Koeveringe GA, Martinez-Martinez P, de Vente J, Gillespie JI. 2009. M3 muscarinic receptor expression on suburothelial interstitial cells. BJU Int. 104:398-405
36. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. 2005. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br. J. Pharmacol. 144:1089-99
37. Bschleipfer T, Schukowski K, Weidner W, Grando SA, Schwantes U, et al. 2007. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci. 80:2303-7
38. Braverman AS, Lebed B, Linder M, Ruggieri MR Sr. 2007. M2 mediated contractions of human bladder from organ donors is associated with an increase in urothelial muscarinic receptors. Neurourol. Urodyn. 26:63-70
39. Arrighi N, Bodei S, Lucente A, Michel MC, Zani D, et al. 2011. Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa. Pharmacol. Res. 64:420-25
40. Barendrecht MM, Chichester P, Michel MC, Levin RM. 2007. Effect of short-term outlet obstruction on rat bladder nerve density and contractility. Auton. Autacoid Pharmacol. 27:47-54
41. Wuest M, Kaden S, Hakenberg OW, Wirth MP, Ravens U. 2005. Effect of rilmakalim on detrusor contraction in the presence and absence of urothelium. Naunyn-Schmiedebergs Arch. Pharmacol. 372:203-12
42. Michel MC. 2014. Do β-Adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder? Naunyn-Schmiedebergs Arch. Pharmacol. 387:215-24
43. Klausner AP, Rourke KF, Miner AS, Ratz PH. 2009. Potentiation of carbachol-induced detrusor smooth muscle contractions by β-Adrenoceptor activation. Eur. J. Pharmacol. 606:191-98
44. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. 2000. Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br. J. Pharmacol. 129:416-19
45. Murakami S, Chapple CR, Akino H, Sellers DJ, Chess-Williams R. 2007. The role of the urothelium in mediating bladder responses to isoprenaline. BJU Int. 99:669-73
46. Sadananda P, Chess-Williams R, Burcher E. 2008. Contractile properties of the pig bladder mucosa in response to neurokinin A: A role for myofibroblasts? Br. J. Pharmacol. 153:1465-73
47. Cheng J-T, Yu B-C, Tong Y-C. 2007. Changes of M3-muscarinic receptor protein and mRNA expressions in the bladder urothelium and muscle layer of streptozotocin-induced diabetic rats. Neurosci. Lett. 423:1-5
48. Tong Y-C, Cheng J-T. 2007. Alterations ofM2, 3-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. J. Urol. 178:1537-42
49. Datta SN, Roosen A, Pullen A, Popat R, Rosenbaum TP, et al. 2010. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J. Urol. 184:2578-85
50. Michel MC, Barendrecht MM. 2008. Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol. Ther. 117:297-312
51. Andersson K-E. 2011. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur. Urol. 59:377-86
52. Madersbacher H, Knoll M. 1995. Intravesical application of oxybutynin: mode of action controlling detrusor hyperreflexia: preliminary results. Eur. Urol. 28:340-44
53. Kim Y, Yoshimura N, Masuda H, de Miguel H, Chancellor MB. 2005. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int. 97:400-3
54. Chuang Y-C, Thomas CA, Tyagi S, Yoshimura N, Tyagi P, Chancellor MB. 2008. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. Int. Urogynecol. J. 19:1353-57
55. Kullmann FA, Downs TR, Artim DE, Limberg BJ, Shah M, et al. 2011. Urothelial beta3 adrenergic receptors in the rat bladder. Neurourol. Urodyn. 30:144-50
56. Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S. 2008. Expression and functional role of β-Adrenoceptors in the human urinary bladder. Naunyn-Schmiedebergs Arch. Pharmacol. 377:473-81
57. Tyagi P, Thomas CA, Yoshimura N, Chancellor MB. 2009. Investigations into the presence of functional β1, β2 and β3-adrenoceptors in urothelium and detrusor of human bladder. Int. Braz. J. Urol. 35:76-83
58. Kurizaki Y, Ishizuka O, Imamura T, Ishikawa M, Ichino M, et al. 2013. Relationship between expression of β3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Neurourol. Urodyn. 32:88-91
59. Otsuka A, Kawasaki H, Matsumoto R, Shinbo H, Kurita Y, et al. 2013. Expression of β-Adrenoceptor subtypes in urothelium, interstitial cells and detrusor of the human urinary bladder. Neurourol. Urodyn. 5:173-80
60. Nomiya M, Yamaguchi O. 2003. A quantitative analysis of mRNA expression of β1 and β-Adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J. Urol. 170:649-53
61. Frazier EP, Mathy M-J, Peters SLM, Michel MC. 2005. Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol? J. Pharmacol. Exp. Ther. 313:260-67
62. Masunaga K, Chapple CR, McKay NG, Yoshida M, Sellers DJ. 2010. The β3-adrenoceptor mediates the inhibitory effects of β-Adrenoceptor agonists via the urothelium in pig bladder dome. Neurourol. Urodyn. 29:1320-25
63. Propping S, Wuest M, Eichhorn B, Grimm M, Wirth M, et al. 2009. Role of urothelium on β3- adrenoceptor mediated relaxation in human detrusor muscle. Neurourol. Urodyn. 28:870-71
64. Mangera A, Apostolidis A, AnderssonK-E, Dasgupta P, Giannantoni A, et al. 2014. Anupdated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur. Urol. 65:981-90
65. Kuo H-C, Liu H-T, Chuang Y-C, Birder L, Chancellor MB. 2014. Pilot study of liposome-encapsulated onabotulinumtoxinA for patients with overactive bladder: A single-center study. Eur. Urol. 65:1117-24
66. Michel MC. 2014. OnabotulinumtoxinA: how deep shall it go? Eur. Urol. 65:1125-27
67. Hanna-Mitchell AT, Wolf-Johnston AS, Barrick SR, Kanai AJ, Chancellor MB, et al. 2014. Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. Neurourol. Urodyn. In press. doi: 10. 1002/nau. 22508
68. Collins VM, Daly DM, Liaskos M, McKay NG, Sellers D, et al. 2013. OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibitsATPrelease from the urothelium. BJU Int. 112:1018-26
69. Smith CP, Gangitano DA, Munoz A, Salas NA, Boone TB, et al. 2008. Botulinum toxin typeAnormalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem. Int. 52:1068-75
70. Ha US, Park EY, Kim JC. 2011. Effect of botulinum toxin on expression of nerve growth factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats with bladder outlet obstruction-induced detrusor overactivity. Urology 78:721. e1-6
71. Kurizaki Y, Ishizuka O, Imamura T, Ichino M, Ogawa T, et al. 2011. Relation between expression of β1-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Scand. J. Urol. Nephrol. 45:15-19
72. Walden PD, Durkin MM, Lepor H, Wetzel JM, Gluchowski C, Gustafson EL. 1997. Localization of mRNA and receptor binding sites for the α1A-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J. Urol. 157:1032-38
73. Ishihama H, Momota Y, Yanase H, Wang X, de Groat WC, Kawatani M. 2006. Activation of α1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J. Urol. 175:358-64
74. Jensen BC, Swigart PM, Simpson PC. 2009. Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn-Schmiedebergs Arch. Pharmacol. 379:409-12
75. Apodaca G, Balestreire E, Birder LA. 2007. The uroepithelial-associated sensory web. Kidney Int. 72:1057-64
76. Gillespie JI, van Koeveringe GA, de Wachter SG, de Vente J. 2009. On the origins of the sensory output from the bladder: the concept of afferent noise. BJU Int. 103:1324-33
77. Andersson K-E. 2010. Detrusor myocyte activity and afferent signaling. Neurourol. Urodyn. 29:97-106
78. de Groat WC, Yoshimura N. 2010. Changes in afferent activity after spinal cord injury. Neurourol. Urodyn. 29:63-76
79. Wyndaele J-J. 2010. Investigating afferent nerve activity from the lower urinary tract: highlighting some basic research techniques and clinical evaluation methods. Neurourol. Urodyn. 29:56-62
80. Nandigama R, Bonitz M, Papadakis T, Schwantes U, Bschleipfer T, Kummer W. 2010. Muscarinic acetylcholine receptor subtypes expressed by mouse bladder afferent neurons. Neuroscience 168:842-50
81. Bschleipfer T, Nandigama R, Moeller S, Illig C, Weidner W, Kummer W. 2012. Bladder outlet obstruction influences mRNA expression of cholinergic receptors on sensory neurons in mice. Life Sci. 91:1077-81
82. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB. 2005. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 65:238-42
83. Hedlund P, Streng T, Lee T, Andersson K-E. 2007. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J. Urol. 178:326-31
84. Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H. 2005. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J. Urol. 174:2032-36
85. Daly DM, Chess-Williams R, Chapple C, Grundy D. 2010. The inhibitory role of acetylcholine and muscarinic receptors in bladder afferent activity. Eur. Urol. 58:22-28
86. de Laet K, de Wachter S, Wyndaele J-J. 2006. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol. Urodyn. 25:156-61
87. Iijima K, de Wachter S, Wyndaele J-J. 2007. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur. Urol. 52:842-49
88. Yu Y, de Groat WC. 2010. Effects of stimulation of muscarinic receptors on bladder afferent nerves in the in vitro bladder-pelvic afferent nerve preparation of the rat. Brain Res. 1361:43-53
89. Aizawa N, Homma Y, Igawa Y. 2012. Effects of mirabegron, a novel β3-adrenoceptor agonist, on the primary bladder afferent activity and bladder microcontractions in rats in comparison with those of oxybutynin. Eur. Urol. 62:1166-73
90. Aizawa N, Igawa Y, Nishizawa O, Wyndaele J-J. 2010. Effects of CL316, 243, aβ3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol. Urodyn. 29:771-76
91. Patra PB, Thorneloe KS. 2011. Enhanced sensitivity to afferent stimulation and impact of overactive bladder therapies in the conscious, spontaneously hypertensive rat. J. Pharmacol. Exp. Ther. 338:392-99
92. Apostolidis A, Dasgupta P, Fowler CJ. 2006. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur. Urol. 49:644-50
93. Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. 2008. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 101:366-70
94. Kanai A, Wyndaele J-J. 2011. Researching bladder afferents-determining the effects of β3-adrenergic receptor agonists and botulinum toxin type-A. Neurourol. Urodyn. 30:684-91
95. Yoshiyama M, de Groat WC. 2001. Role of spinal α1-adrenoceptor subtypes in the bladder reflex in anesthetized rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280:R1414-19
96. Yokoyama O, Yusup A, Oyama N, Aoki Y, Tanase K, et al. 2006. Improvement of bladder storage function by α1-blocker depends on the suppression of C-fiber afferent activity in rats. Neurourol. Urodyn. 25:461-67
97. Yokoyama O, Ito H, Aoki Y, Oyama N, Miwa Y, Akino H. 2010. Selective α1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity. World J. Urol. 28:609-14
98. Fowler CJ, Griffiths D, de Groat WC. 2008. The neural control of micturition. Nat. Rev. Neurosci. 9:453-66
99. Drake MJ, Tannenbaum C, Kanai AJ. 2010. Potential insights into lower urinary function derived from CNS imaging. Neurourol. Urodyn. 29:629-33
100. Fowler CJ, Griffiths DJ. 2010. A decade of functional brain imaging applied to bladder control. Neurourol. Urodyn. 29:49-55
101. Yoshimura N, Miyazoto M, Kitta T, Yoshikawa S. 2014. Central nervous targets for the treatment of bladder dysfunction. Neurourol. Urodyn. 33:59-66
102. Michel MC, Radziszeswski P, Falconer C, Marschall-Kehrel D, Rundfeldt C, Vanhoutte F. 2008. The centrally acting ion channel modulator flupirtine improves bladder function in animal models and patients with overactive bladder syndrome. Presented at Int. Cont. Soc. 2008, Oct. 20-24, Cairo. http://www. icsoffice. org/Abstracts/Publish/46/000406. pdf
103. Dale PR, Cernecka H, Schmidt M, Dowing M, Charlton SJ, Michel MC. 2014. The pharmacological rationale for combining muscarinic receptor antagonists and β-Adrenoceptor agonists in the treatment of airway and bladder disease. Curr. Opin. Pharmacol. 16:31-42
104. Somogyi GT, Tanowitz M, de Groat WC. 1995. Prejunctional facilitatory β1-adrenoceptors in the rat urinary bladder. Br. J. Pharmacol. 114:1710-16
105. Szell EA, Yamamoto T, de Groat WC, Somogyi GT. 2000. Smooth muscle and parasympathetic nerve terminals in the rat urinary bladder have different subtypes of β1 adrenoceptors. Br. J. Pharmacol. 130:1685-91
106. Messori E, Rizzi CA, Candura SM, Lucchelli A, Balestra B, Tonini M. 1995. 5-Hydroxytryptamine receptors that facilitate excitatory neuromuscular transmission in the guinea-pig isolated detrusor muscle. Br. J. Pharmacol. 115:677-83
107. Candura SM, Messori E, Fraceschetti GP, DAgostino G, Vicini D, et al. 1996. Neural 5-HT4 receptors in human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists. Br. J. Pharmacol. 118:1965-70
108. Chetty N, Coupar IM, Chess-Williams R, Kerr KP. 2007. Demonstration of 5-HT3 receptor function and expression in the mouse bladder. Naunyn-Schmiedebergs Arch. Pharmacol. 375:359-68
109. Tsurusaki M, Yoshida M, Akasu T, Nagatsu I. 1990. α2-Adrenoceptors mediate the inhibition of cholinergic transmission in parasympathetic ganglia of the rabbit urinary bladder. Synapse 5:233-40
110. Zoubek J, Somogyi GT, de Groat WC. 1993. A comparison of inhibitory effects of neuropeptide Y on rat urinary bladder, urethra, and vas deferens. Am. J. Physiol. Regul. Integr. Comp. Physiol. 265:R537-43
111. Tran LV, Somogyi GT, de Groat WC. 1994. Inhibitory effect of neuropeptide Y on adrenergic and cholinergic transmission in rat urinary bladder and urethra. Am. J. Physiol. Regul. Integr. Comp. Physiol. 266:R1411-17
112. Davis B, Goepel M, Bein S, Chess-Williams R, Chapple CR, Michel MC. 2000. Lack of neuropeptide Y receptor detection in human bladder and prostate. BJU Int. 85:918-24
113. Elbadawi A, Diokno AC, Millard RJ. 1998. The aging bladder: morphology and urodynamics. World J. Urol. 16(Suppl. 1):S10-34
114. Golbidi S, Laher I. 2010. Bladder dysfunction in diabetes mellitus. Front. Pharmacol. 1:136
115. Grol S, Nile CJ, Martinez-Martinez P, vanKoeveringe GA, de Wachter SGG, et al. 2011. M3 muscarinic receptor-like immunoreactivity in sham-operated and obstructed guinea pig bladders. J. Urol. 185:1959- 66
116. Ochodnicky P, Uvelius B, Andersson K-E, Michel MC. 2013. Autonomic nervous control of the urinary bladder. Acta Physiol. 207:16-33
117. Cumming JA, Chisholm GD. 1992. Changes in detrusor innervation with relief of outflow tract obstruction. Br. J. Urol. 69:7-11
118. Chapple CR, Milner P, Moss HE, Burnstock G. 1992. Loss of sensory neuropeptides in the obstructed human bladder. Br. J. Urol. 70:373-81
119. Nilvebrant L, Ekstr om J, Malmberg L. 1986. Muscarinic receptor density in the rat urinary bladder after denervation, hypertrophy and urinary diversion. Acta Pharmacol. Toxicol. 59:306-14
120. Tuttle JB, Steers WD, Albo M, Nataluk E. 1994. Neural input regulates tissue NGF and growth of the adult rat urinary bladder. J. Auton. Nerv. Syst. 49:147-48
121. Braverman AS, Luthin GR, Ruggieri MR. 1998. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am. J. Physiol. Regul. Integr. Comp. Physiol. 275:R1654-60
122. Braverman AS, RuggieriMR Sr. 2003. Hypertrophy changes the muscarinic receptor subtypemediating bladder contraction from M3 toward M2. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285:R701-8
123. Vizzard MA. 2000. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp. Neurol. 161:273-84
124. Turner WH, Brading AF. 1999. Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment. Pharmacol. Ther. 75:77-110
125. Yamaguchi O. 2004. Response of bladder smooth muscle cells to obstruction: signal transduction and the role of mechanosensors. Urology 63:11-16
126. Fry CH, Skennerton D, Wood D, Wu C. 2002. The cellular basis of contraction in human detrusor smooth muscle from patients with stable and unstable bladders. Urology 59(Suppl. 5A):3-12
127. Fry CH, Sui GP, Severs NJ, Wu C. 2004. Spontaneous activity and electrical coupling in human detrusor smooth muscle: implications for detrusor overactivity? Urology 63(Suppl. 3A):3-10
128. Roosen A, Chapple CR, Dmochowski RR, Fowler CJ, Gratzke C, et al. 2009. A refocus on the bladder as the originator of storage lower urinary tract symptoms: A systematic review of the latest literature. Eur. Urol. 56:810-20
129. Hegde SS. 2006. Muscarinic receptors in the bladder: from basic research to therapeutics. Br. J. Pharmacol. 147:S80-87
130. Braverman AS, Ruggieri MR Sr. 2006. Muscarinic receptor transcript and protein density in hypertrophied and atrophied rat urinary bladder. Neurourol. Urodyn. 25:55-61
131. Peters SLM, Schmidt M, Michel MC. 2006. Rho kinase: A target for treating urinary bladder dysfunction? Trends Pharmacol. Sci. 27:492-97
132. Frazier EP, Peters SLM, Braverman AS, Ruggieri MR Sr, Michel MC. 2008. Signal transduction underlying control of urinary bladder smooth muscle tone by muscarinic receptors and β-Adrenoceptors. Naunyn-Schmiedebergs Arch. Pharmacol. 377:449-62
133. Witte LPW, de Haas N, Mammen M, Stangeland EL, Steinfeld T, et al. 2011. Muscarinic receptor subtypes and signalling involved in the attenuation of isoprenaline-induced rat urinary bladder relaxation. Naunyn-Schmiedebergs Arch. Pharmacol. 384:555-63
134. Johnston L, Carson C, Lyons AD, Davidson RA, McCloskey KD. 2008. Cholinergic-induced Ca2+ signaling in interstitial cells of Cajal from the guinea pig bladder. Am. J. Physiol. Ren. Physiol. 294:F645- 55
135. Michel MC, Vrydag W. 2006. β1-, β2- andβ-Adrenoceptors in the urinary bladder, urethra and prostate. Br. J. Pharmacol. 147:S88-119
136. Igawa Y, Schneider T, Yamazaki Y, Tatemichi S, Homma Y, et al. 2012. Functional investigation of β-Adrenoceptors in human isolated detrusor focusing on the novel selective β3-adrenoceptor agonist KUC-7322. Naunyn-Schmiedebergs Arch. Pharmacol. 385:759-67
137. Levin RM, Levin SS, Zhao Y, Buttyan R. 1997. Cellular and molecular aspects of bladder hypertrophy. Eur. Urol. 32(Suppl. 1):15-21
138. Levin RM, English M, Barretto M, Dubuc M, OConnor L, et al. 2000. Normal detrusor is more sensitive than hypertrophied detrusor to in vitro ischemia followed by re-oxygenation. Neurourol. Urodyn. 19:701-12
139. Pessina F, Marazova K, Ninfali P, Avanzi L, Manfredini S, Sgaragli G. 2004. In vitro neuroprotection by novel antioxidants in guinea-pig urinary bladder subjected to anoxia/reperfusion damage. Naunyn- Schmiedebergs Arch. Pharmacol. 370:521-28
140. Yamaguchi O, Nomiya M, Andersson K-E. 2014. Functional consequences of chronic bladder ischemia. Neurourol. Urodyn. 33:54-58
141. Ishida T, Shimoda N, Sato K, Ogawa O, Nishizawa O, Kato T. 1999. Effects of ischemia on voiding function and nerve growth factor on the rat urinary bladder. Jpn. J. Urol. 90:564-71
142. Okutsu H, Matsumoto S, Hanai T, Noguchi Y, Fujiyasu N, et al. 2010. Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction. Urology 75:235-40
143. Inoue S, Saito M, Tsounapi P, Dimitriadis F, Ohmasa F, et al. 2012. Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat. BJU Int. 110:E118-24
144. Sawada N, Nomiya M, Hood B, Koslov D, Zarifpour M, Andersson K-E. 2013. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur. Urol. 64:664-71
145. Yono M, Pouresmail M, Takahashi W, Flanagan JF, Weiss RM, Latifpour J. 2005. Effect of insulin treatment on tissue size of the genitourinary tract in BB rats with spontaneously developed and streptozotocininduced diabetes. Naunyn-Schmiedebergs Arch. Pharmacol. 372:251-55
146. Panayi DC, Tekkis P, Fernando R, Hendricken C, Khullar V. 2010. Ultrasoundmeasurement of bladder wall thickness is associated with the overactive bladder syndrome. Neurourol. Urodyn. 29:1295-98
147. Myers JB, DallEra JE, Koul S, Kumar B, Khandrika L, et al. 2009. Biochemical alterations in partial bladder outlet obstruction in mice: up-regulation of the mitogen activated protein kinase pathway. J. Urol. 181:1926-32
148. Soler R, Andersson K-E, Chancellor MB, Chapple CR, de Groat WC, et al. 2013. Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur. Urol. 64:610-21
149. U ckert S, Oelke M. 2011. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br. J. Clin. Pharmacol. 72:197-204
150. Leiria LO, Silva FH, Davel APC, Alexandre ED, Calixto MC, et al. 2014. The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice. J. Urol. 191:539-47
151. Frias B, Charrua A, Avelino A, Michel MC, Cruz F, Cruz CD. 2012. Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input. BJU Int. 110:E422-28
152. Franken J, Uvin P, de Ridder D, Voets T. 2014. TRP channels in lower urinary tract dysfunction. Br. J. Pharmacol. 171:2537-51